Format

Send to

Choose Destination
Niger Postgrad Med J. 2019 Oct-Dec;26(4):195-198. doi: 10.4103/npmj.npmj_75_19.

Absence of human leukocyte antigen-B*57:01 amongst patients on antiretroviral therapy in Nigeria: Implications for use of abacavir.

Author information

1
Department of Medicine, University of Jos/Jos University Teaching Hospital; Department of AIDS Prevention Initiative in Nigeria (APIN)-Supported HIV Treatment Centre, Jos University Teaching Hospital, Jos, Nigeria.
2
Department of Medicine, University of Jos/Jos University Teaching Hospital; Department of AIDS Prevention Initiative in Nigeria (APIN)-Supported HIV Treatment Centre, Jos University Teaching Hospital, Jos, Nigeria; Health Sciences Integrated PhD Program, Center for Education in Health Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
3
Department of AIDS Prevention Initiative in Nigeria (APIN)-Supported HIV Treatment Centre, Jos University Teaching Hospital, Jos, Nigeria.
4
Department of AIDS Prevention Initiative in Nigeria (APIN)-Supported HIV Treatment Centre, Jos University Teaching Hospital; Department of Family Medicine, University of Jos/Jos University Teaching Hospital, Jos, Nigeria.
5
Department of Molecular Biology Research Laboratory, Lagos University Teaching Hospital, Lagos, Nigeria.
6
Department of Hematology, Ahmadu Bello University/Ahmadu Bello University Teaching Hospital, Zaria, Nigeria.
7
Department of Hematology, College of Medicine, University of Lagos/Lagos University Teaching Hospital, Lagos, Nigeria.
8
Department of Medicine, Federal Medical Centre, Yenagoa, Nigeria.
9
Department of Family Medicine, Federal Medical Centre, Makurdi, Nigeria.

Abstract

Background:

The presence of human leukocyte antigen (HLA) B*57:01 allele predicts hypersensitivity reaction (HSR) to abacavir (ABC), a nucleoside reverse-transcriptase inhibitor used for human immunodeficiency virus (HIV) treatment. However, the prevalence of this allele amongst Nigerians with HIV is yet to be established. We aimed to determine the prevalence of HLA-B*57:01 allele amongst Nigerians with HIV infection.

Methods:

We conducted a multicentre cross-sectional epidemiologic survey. Between April 2016 and April 2017, patients were enrolled across five HIV treatment facilities in Nigeria. Participants' demographic information and their history of ABC exposure were obtained, and venous blood was obtained for HLA typing.

Results:

One thousand five hundred and four (1504) adults were enrolled, with a mean age of 44.6 ± 10.7 years, 1078 (71.7%) were female. 1463 (97.3%) were on antiretroviral therapy. ABC use was reported by 12 (0.8%) participants and none reported HSR. Of 1500 blood samples that were processed, 1458 (97.2%) were successfully typed. Of these, 132 (9.1%) were HLA-B*57 positive using non-specific low-resolution HLA-B*5701 primer mix. On further analysis, none of the 132 samples (0%) had the HLA-B*5701 allele.

Conclusion:

HLA-B*5701allele is rare amongst Nigerians.

KEYWORDS:

Abacavir; Africa; antiretroviral therapy; epidemiology; human immunodeficiency virus; hypersensitivity

PMID:
31621657
DOI:
10.4103/npmj.npmj_75_19
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center